I. Odeyemi

发表

Modelling the economic impact of recombinant activated Factor VII and activated prothrombin-complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX at a comprehensive care centre in the UK

J. Guest, I. Odeyemi, 2002 .

Modelling the economic impact of recombinant activated Factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX in the UK

J. Guest, I. Odeyemi, 2002 .

Patient‐reported outcomes with the β3‐adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder

G. Amarenco, M. B. Blauwet, J. Nazir, 2016, Neurourology and urodynamics.

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

C. Kelleher, S. Aballéa, C. Mankowski, 2018, Journal of Market Access & Health Policy.

Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service

J. Posnett, A. Garnham, J. Nazir, 2015, Journal of medical economics.

Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.

A. Garnham, S. Aballéa, J. Nazir, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom

A. Garnham, M. Toumi, S. Aballéa, 2014, Clinical Drug Investigation.

A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome

A. Mundy, M. Speakman, I. Odeyemi, 2008, Current medical research and opinion.

Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research.

I. Wiklund, S. Holmstrom, T. Wilcox, 2012, Drug discovery today.

A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability

I. Odeyemi, R. Pollock, G. Muduma, 2014, Journal of medical economics.

Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron

M. Herdman, N. Devlin, M. Pavesi, 2013, Journal of medical economics.

Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK

I. Odeyemi, R. Pollock, G. Muduma, 2015, Journal of medical economics.

Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales

I. Odeyemi, W. Hart, G. Muduma, 2014, Patient preference and adherence.

The impact of the overactive bladder on health‐related utility and quality of life

S. Datta, P. McEwan, C. Poole, 2006, BJU international.

Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients

J. Smith-Palmer, I. Odeyemi, R. Pollock, 2016, Advances in Therapy.

Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta‐analysis

C. Kelleher, S. Aballéa, C. Mankowski, 2018, Neurourology and urodynamics.

Burden of cytomegalovirus disease in allogeneic hematopoietic cell transplant recipients: a national, matched cohort study in an inpatient setting.

I. Yakoub-Agha, M. Toumi, S. Aballéa, 2018, Current research in translational medicine.

Optimising immune tolerance induction strategies in the management of haemophilia patients with inhibitors: a cost-minimisation analysis

I. Odeyemi, A. Danø, 2009, Current medical research and opinion.

De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections

R. Zinck, R. Masterton, I. Odeyemi, 2013, Journal of Medical Economics.

Optimising immune tolerance induction strategies in the management of haemophilia patients with inhibitors: a cost-minimisation analysis.

I. Odeyemi, A. Danø, 2009, Current medical research and opinion.

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation

B. Tombal, A. Abou-Setta, I. Odeyemi, 2013, ClinicoEconomics and outcomes research : CEOR.

Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence

J. Smith-Palmer, I. Odeyemi, R. Pollock, 2013, Patient preference and adherence.

Community-based health insurance programmes and the national health insurance scheme of Nigeria: challenges to uptake and integration

I. Odeyemi, 2014, International Journal for Equity in Health.

Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study

C. Poole, C. Currie, E. Berni, 2017, BMC Neurology.

“De-escalation” strategy using micafungin for the treatment of systemic Candida infections: budget impact in France and Germany

I. Odeyemi, A. V. van Engen, Soyoung Kim, 2017, ClinicoEconomics and outcomes research : CEOR.

“ Deescalation ” strategy using micafungin for the treatment of systemic Candida infections : budget impact in France and Germany

I. Odeyemi, Soyoung Kim, M. Watt, 2017 .

Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.

S. Aballéa, J. Nazir, I. Odeyemi, 2014, European urology.

Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre.

P. Dasgupta, C. Fowler, J. Warner, 2006, European urology.

Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting

M. Toumi, S. Aballéa, F. Saliba, 2017, Transplant infectious disease : an official journal of the Transplantation Society.

Responder and health‐related quality of life analyses in men with lower urinary tract symptoms treated with a fixed‐dose combination of solifenacin and tamsulosin oral‐controlled absorption system: results from the NEPTUNE study

K. Coyne, M. Oelke, M. Drake, 2016, BJU international.

Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant

I. Odeyemi, R. Pollock, R. Saunders, 2016, PloS one.

Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.

D. Nathwani, C. Ivanescu, O. Cornely, 2014, The Journal of antimicrobial chemotherapy.

Assessing equity in health care through the national health insurance schemes of Nigeria and Ghana: a review-based comparative analysis

J. Nixon, I. Odeyemi, 2013, International Journal for Equity in Health.

Validation of the Patient Perception of Intensity of Urgency Scale in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.

R. Crosby, J. Nazir, I. Odeyemi, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK

I. Odeyemi, R. Pollock, G. Muduma, 2016, Journal of medical economics.

Deriving health state utilities for the numerical pain rating scale

S. Dixon, C. Poole, C. Currie, 2011, Health and quality of life outcomes.

An economic evaluation of the impact of the privatisation policy on animal health delivery services in africa : a case study of Zimbabwe

I. Odeyemi, 1999 .

The role and uptake of private health insurance in different health care systems: are there lessons for developing countries?

J. Nixon, I. Odeyemi, 2013, ClinicoEconomics and outcomes research : CEOR.

Indicators of Health-Related Quality of Life in Cats With Degenerative Joint Disease: Systematic Review and Proposal of a Conceptual Framework

I. Odeyemi, T. Gebrye, G. Yeowell, 2021, Frontiers in Veterinary Science.

Cost Effectiveness Of Solifenacin Compared With Oral Antimuscarinic Agents For The Treatment Of Patients With Overactive Bladder (Oab) In The Uk.

S. Aballéa, J. Nazir, I. Odeyemi, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Content validity and test-retest reliability of patient perception of intensity of urgency scale (PPIUS) for overactive bladder

D. Revicki, I. Odeyemi, T. Marshall, 2012, BMC Urology.

Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data

Michelle E Johnson, B. Blak, J. Nazir, 2015, Current medical research and opinion.

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

S. Aballéa, J. Nazir, I. Odeyemi, 2013, Health and Quality of Life Outcomes.

Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice

I. Odeyemi, R. Pollock, G. Muduma, 2016, Drugs - Real World Outcomes.

Patient survey to identify reasons for non-adherence and elicitation of quality of life concepts associated with immunosuppressant therapy in kidney transplant recipients

M. Toumi, S. Aballéa, I. Odeyemi, 2016, Patient preference and adherence.

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection

D. Nathwani, O. Cornely, I. Odeyemi, 2014, The Journal of antimicrobial chemotherapy.

Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia

M. Herdman, N. Devlin, M. Pavesi, 2017, Quality of Life Research.

"Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making.

Nancy J Devlin, N. Devlin, H. Dakin, 2006, Health policy.

Original article Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service

J. Posnett, J. Nazir, I. Odeyemi, 2015 .

Poster abstracts

B. Schurch, C. Fowler, P. Zvára, 2010, Neurotoxicity Research.

Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany

I. Odeyemi, M. Sidhu, A. V. van Engen, 2008, Current medical research and opinion.

Patient survey to identify reasons for non-adherence and elicitation of quality of life concepts associated with immunosuppressant therapy in kidney transplant recipients

M. Toumi, S. Aballéa, I. Odeyemi, 2016 .

Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice

I. Odeyemi, R. Pollock, G. Muduma, 2016, Drugs - real world outcomes.

Clinicoeconomics and Outcomes Research

B. Tombal, A. Abou-Setta, I. Odeyemi, 2022 .